Optimizing care of heart failure after acute MI with an aldosterone receptor antagonist

Current Heart Failure Reports

Volumn 4, Issue 4, 2007, Pages 183-189

  Verma, Anil ^c   Solomon, Scott D ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE; ALDOSTERONE ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; SPIRONOLACTONE;

ACUTE HEART INFARCTION; DISEASE COURSE; DRUG ACTIVITY; EVIDENCE BASED PRACTICE; HEART FAILURE; HUMAN; HYPERKALEMIA; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR; SURVIVAL;

ALDOSTERONE ANTAGONISTS; EVIDENCE-BASED MEDICINE; HEART FAILURE; HUMANS; HYPERKALEMIA; MYOCARDIAL INFARCTION; RECEPTORS, ALDOSTERONE; RISK FACTORS; SPIRONOLACTONE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 38049032390     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-007-0011-8     Document Type: Review

References (38)

1. Antman EM, Anbe DT, Armstrong PW, et al.: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction - executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation 2004, 110:588-636. These are ACC/AHA-recommended evidence-based guidelines for the management of patients with ST elevation acute MI. Risk stratification and drug therapy are included.
2. Guidry UC, Evans JC, Larson MG, et al.: Temporal trends in event rates after Q-wave myocardial infarction: the Framingham Heart Study. Circulation 1999, 100:2054-2059.
3. Haber E: George C. Griffith lecture. The role of renin in normal and pathological cardiovascular homeostasis. Circulation 1976, 54;849-861.
4. Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709-717.
5. Pitt B, Remme W, Zannad F, et al.; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309-1321. [Published correction appears in N Engl J Med 2003, 348:2271.]
6. Weber KT, Sun Y: Recruitable ACE and tissue repair in the infarcted heart. J Renin Angiotensin Aldosterone Syst 2000, 1:295-303.
7. Weber KT, Brilla CG, Campbell SE, et al.: Myocardial fibrosis: role of angiotensin II and aldosterone. Basic Res Cardiol 1993, 88(Suppl 1)107-124.
8. Hunt SA, Abraham WT, Chin MH, et al.: ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005, 112:e154-e235. ACC/AHA-recommended evidence-based guidelines for the management of patients with chronic heart failure. The management of patients with heart failure after MI and the use of aldosterone receptor blockers are also discussed.
9. Swedberg K, Cleland J, Dargie H, et al.: Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). Eur Heart J 2005, 26:1115-1140. Evidence-based guidelines from the European Society of Cardiology for the management of patients with chronic heart failure.
10. Struthers AD: Aldosterone blockade in cardiovascular disease. Heart 2004, 90:1229-1234. This review discusses biology and mechanistic issues of aldosterone in cardiovascular diseases.
11. Lal A, Veinot JP, Ganten D, Leenen FH: Prevention of cardiac remodeling after myocardial infarction in transgenic rats deficient in brain angiotensinogen. J Mol Cell Cardiol 2005, 39:521-529. After MI, transgenic rats deficient in brain angiotensinogen and Wistar rats with intracerebroventricular infusion of spironolactone were studied to assess the contribution of the brain RAAS in the activation of the cardiac RAAS. The increase in cardiac aldosterone after MI was shown to depend on the central RAAS.
12. Opie LH, Commerford PJ, Gersh BJ, Pfeffer MA: Controversies in ventricular remodelling. Lancet 2006, 367:356-367. This review discusses ventricular remodeling and describes structural changes in the left ventricle in response to chronic alterations in loading conditions and potential novel therapies for these disorders.
13. Delcayre C, Silvestre JS, Garnier A, et al.: Cardiac aldosterone production and ventricular remodeling. Kidney Int 2000, 57:1346-1351.
14. Silvestre JS, Heymes C, Oubenaissa A, et al.: Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation 1999, 99:2694-2701.
15. Hayashi M, Tsutamoto T, Wada A, et al.: Relationship between transcardiac extraction of aldosterone and left ventricular remodeling in patients with first acute myocardial infarction: extracting aldosterone through the heart promotes ventricular remodeling after acute myocardial infarction. J Am Coll Cardiol 2001, 38:1375-1382.
16. Hein S, Arnon E, Kostin S, et al.: Progression from compensated hypertrophy to failure in the pressure-overloaded human heart. Structural deterioration and compensatory mechanisms. Circulation 2003, 107:984-991.
17. Modena MG, Aventa P, Menozzi PM, Rossi R: Aldosterone inhibition limits collagen synthesis and progressive left ventricular enlargement after anterior myocardial infarction. Am Heart J 2001, 141:41-46.
18. Poulsen SH, Host NB, Jensen SE, Egstrup K: Relationship between serum amino-terminal propeptide of type III procollagen and changes of left ventricular function after acute myocardial infarction. Circulation 2000, 101:1527-1532.
19. Zannad F, Alla F, Dousset B, et al.: Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure. Circulation 2000, 102:2700-2706.
20. Katada J, Meguro T, Saito H, et al.: Persistent cardiac aldosterone synthesis in angiotensin II type 1A receptor-knockout mice after myocardial infarction. Circulation 2005, 111:2157-2164. Acute MI was induced in wild-type and angiotensin II type IA receptor-knockout (AT1A) mice, and the researchers observed that genetic blockade of AT1A signaling failed to arrest aldosterone production in cardiac tissues and that cardiac aldosterone played a critical role in post-MI LV remodeling.
21. Staessen J, Lijnen P, Fagard R, et al.: Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol 1981, 91:457-465.
22. Borghi C, Boschi S, Ambrosioni E, et al.: Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors. J Clin Pharmacol 1993, 33:40-45.
23. Tang WH, Vagelos RH, Yee YG, et al.: Neurohormonal and clinical responses to high- versus low-dose enalapril therapy in chronic heart failure. J Am Coll Cardiol 2002, 39:70-78. [Published correction appears in J Am Coll Cardiol 2002, 39:746].
24. Tang WH, Parameswaran AC, Maroo AP, Francis GS: Aldosterone receptor antagonists in the medical management of chronic heart failure. Mayo Clin Proc 2005, 80:1623-1630. This excellent review article discusses the role of aldosterone in the pathophysiology of heart failure as well as the pharmacology and efficacy of aldosterone receptor antagonists in heart failure.
25. Bauersachs J, Heck M, Fraccarollo D, et al.: Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: role of vascular superoxide anion formation and endothelial nitric oxide synthase expression. J Am Coll Cardiol 2002, 39:351-358.
26. Farquharson CA, Struthers AD: Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000, 101:594-597.
27. Barr CS, Lang CC, Hanson J, et al.: Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1995, 76:1259-1265.
28. Dyckner T, Wester PO, Widman L: Effects of spironolactone on serum and muscle electrolytes in patients on long-term diuretic therapy for congestive heart failure and/or arterial hypertension. Eur J Clin Pharmacol 1986, 30:535-540.
29. Pitt B, Pitt GS: Added benefit of mineralocorticoid receptor blockade in the primary prevention of sudden cardiac death. Circulation 2007, 115:2976-2982. This review discusses potential mechanisms by which mineralocorticoid receptor blockers reduce sudden cardiac death and proposes opportunities for further reducing sudden cardiac death in high-risk individuals without LV systolic dysfunction or heart failure.
30. Cohn JN, Colucci W: Cardiovascular effects of aldosterone and post-acute myocardial infarction pathophysiology. Am J Cardiol 2006, 97(Suppl):4F-12F. This article discusses the role of aldosterone in post-MI cardiovascular pathophysiology and the benefits of its blockade in patients with post-MI heart failure.
31. Pitt B, White H, Nicolau J, et al.: Eplerenone reduces mortality 30 days postrandomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol 2005, 46:425-431. The effect of eplerenone 25 mg/d initiated 3 to 14 days after MI was evaluated on the mortality from any cause and the composite end point of death from cardiovascular causes after 30 days of therapy in EPHESUS. The authors reported a 31% reduction in all-cause mortality, 32% reduction in cardiovascular mortality, and a 37% reduction in sudden cardiac death.
32. Solomon SD, Zelenkofske S, McMurray JJV, et al.: Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure or both. N Engl J Med 2005, 352:2581-2588. Risk and time course of sudden death in high-risk patients after MI were assessed in the Valsartan in Acute Myocardial Infarction Trial (VALIANT). The authors observed that the risk of sudden death is highest in the first 30 days after MI among patients with left ventricular dysfunction, heart failure, or both.
33. Banas J, White H, Parkhomenko A, et al.: Favorable outcomes with 25 mg of eplerenone in patients with post-AMI heart failure: results from the EPHESUS trial. J Card Fail 2005, 11(6 Suppl):S156.
34. Pitt B, Ferrari R, Gheorghiade M, et al.: Aldosterone blockade in post-acute myocardial infarction heart failure. Clin Cardiol 2006, 29:434-438.
35. Weintraub WS, Zhang Z, Mahoney EM, et al.: Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure. Circulation 2005, 111:1106-1113.
36. Hohnloser SH, Kuck KH, Dorian P, et al.: Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 2004, 351:2481-2488. Efficacy of implantable cardioverter-defibrillators (ICDs) was evaluated in early post-MI patients. The authors concluded that prophylactic ICD therapy does not reduce overall mortality in high-risk patients who have recently had a MI.
37. Juurlink DN, Mamdani MM, Lee DS, et al: Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004, 351:543-551.
38. Levey AS, Bosch JP, Lewis JB, et al.: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999, 130:461-447.